FDA Approves REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA WT Locally Advanced or Metastatic Breast Cancer July 15, 2026
Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program July 7, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as 1L Treatment of PD-L1+ (CPS ≥10) Advanced TNBC June 30, 2026
Datroway recommended for approval in the EU by CHMP for patients with 1L metastatic TNBC who are not candidates for immunotherapy June 30, 2026
FDA Approves IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance June 30, 2026
First Patient Enrolled in Ph 1b/2 Breast Cancer Study of AK138D1 Combined with Ivonescimab June 17, 2026
Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint June 17, 2026
FDA accepts NDA for giredestrant in ER+ve early-stage breast cancer with positive Ph 3 results in the curative setting June 10, 2026
Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development June 10, 2026
Positive Recommendation from DSMB for Ph 3 Study of Bria-IMT + CPI in Metastatic Breast Cancer June 2, 2026
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Gen Oncology Therapies and $215M Concurrent Private Placement June 2, 2026
FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data June 2, 2026
CHMP Positive Opinion for Trodelvy in 1L Metastatic TNBC for Patients Not Candidates for PD-(L)1 Inhibitors June 2, 2026
Ph 3 Trial of Sacituzumab Tirumotecan (sac-TMT) vs Chemo as 1L Treatment for Advanced TNBC Met Primary Endpoint of PFS May 26, 2026
Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1L advanced ER+ve breast cancer May 26, 2026
Datroway approved in the US in 1L metastatic TNBC patients not PD-1/PD-L1 inhibitor candidates May 26, 2026
Enhertu approved for use before surgery based on DESTINY-Breast11 Ph 3 trial and following surgery based on DESTINY-Breast05 Ph 3 trial in HER2-positive early breast cancer May 21, 2026
Rigel Enters Licensing Agreement for VEPPANU™ (vepdegestrant) for 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer May 21, 2026
Ph 3 VIKTORIA-2 Trial of Gedatolisib in 1L HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients May 21, 2026
Evorpacept + Zanidatamab combo Generates Durable Response in Patients with Advanced HER2+ve Breast Cancer and High CD47 Expression May 12, 2026
